| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Systemic sclerosis (SSc)/ systemic lupus erythematosus (SLE) overlapy syndrome is characterized by the low frequency of lupus nephritis and the high frequency of serositis, but the molecular mechanism underlying this observation has still remianed unknown. To investigate the molecular mechanism regulating the pathological interference between SSc and SLE, we decided to generate a new overlapy syndrome animal model, namely, Klf5+/-;Fli1+/- mice treated with imiquimod, in which double heterozygous loss of KLF5 and Fli1 induces SSc symptoms and imiquimod administration induces lupus symptoms. At the time of writing, we have demonstrated that Klf5+/-;Fli1+/- mice develop cardiac and intestinal symptoms similar to those of SSc without renal invovlement. Now, we are investigating whether imiquimod-induced lupus symptoms are modified in Klf5+/-;Fli1+/- mice. The histological analysis of the skin, lung, heart, kidney, esophagus, and intestine is now on going.
|
